IL6 and rheumatoid arthritis: Therefore, the inhibitory effect of recombinant gp130 on the promotion of IL-6 on osteoclast differentiation at low RANKL level may provide an effective therapeutic approach for the treatment of inflammatory and metabolic osteolytic diseases such as RA and postmenopausal osteoporosis.